These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 11036120)

  • 1. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
    Lowe GD; Rumley A; McMahon AD; Ford I; O'Reilly DS; Packard CJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1529-34. PubMed ID: 15205218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
    Albert MA; Glynn RJ; Wolfert RL; Ridker PM
    Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
    Am J Cardiol; 1997 Mar; 79(6):756-62. PubMed ID: 9070554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 8. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index.
    Santos S; Rooke TW; Bailey KR; McConnell JP; Kullo IJ
    Vasc Med; 2004 May; 9(3):171-6. PubMed ID: 15675180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
    Blake GJ; Dada N; Fox JC; Manson JE; Ridker PM
    J Am Coll Cardiol; 2001 Nov; 38(5):1302-6. PubMed ID: 11691499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
    Sudhir K
    J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
    Corsetti JP; Rainwater DL; Moss AJ; Zareba W; Sparks CE
    Clin Chem; 2006 Jul; 52(7):1331-8. PubMed ID: 16709622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
    N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.
    Winkler K; Winkelmann BR; Scharnagl H; Hoffmann MM; Grawitz AB; Nauck M; Böhm BO; März W
    Circulation; 2005 Mar; 111(8):980-7. PubMed ID: 15710755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
    Folsom AR; Chambless LE; Ballantyne CM; Coresh J; Heiss G; Wu KK; Boerwinkle E; Mosley TH; Sorlie P; Diao G; Sharrett AR
    Arch Intern Med; 2006 Jul; 166(13):1368-73. PubMed ID: 16832001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
    May HT; Horne BD; Anderson JL; Wolfert RL; Muhlestein JB; Renlund DG; Clarke JL; Kolek MJ; Bair TL; Pearson RR; Sudhir K; Carlquist JF
    Am Heart J; 2006 Nov; 152(5):997-1003. PubMed ID: 17070179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study.
    Shepherd J; Gaw A;
    Med Princ Pract; 2002; 11 Suppl 2():17-30. PubMed ID: 12444307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.